Carcinoma of Unknown Primary — Trials

Carcinoma of Unknown Primary — Trials · CancerIndex

Clinical trials

Registered studies

14,232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,156
Recruiting: 2,259
Ph III recruiting: 269
Growth YoY: +12.3%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,893)

clinicaltrialsPublishedShowing 351–400 of 910 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05189067	Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer	unknown	Phase 2 / Phase 3	190	Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER	1	Jan 12, 2022	clinicaltrials
NCT05189184	Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma(HNSCC)	unknown	Phase 2	30	The First Affiliated Hospital of Zhengzhou University